Cargando…

Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model

Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mecha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Fei-lin, Si, Lan-lan, Yang, Yan, Li, Yuan-hua, Lv, Zhong-lin, Liu, Wen-hui, Liao, Hao, Wang, Jun, Zou, Jun, Li, Le, Li, Hui, Zhang, Zi-lin, Wang, Jia-bo, Lu, Xue-chun, Xu, Dong-ping, Bai, Zhao-fang, Liu, Yan, Xiao, Xiao-he
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578813/ https://www.ncbi.nlm.nih.gov/pubmed/34776974 http://dx.doi.org/10.3389/fphar.2021.756975

Ejemplares similares

Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
por: Liu, Huimin, et al.
Publicado: (2018)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
por: Li, Jun, et al.
Publicado: (2023)

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection
por: Li, Pengpeng, et al.
Publicado: (2023)

Letter to the Editor: Entecavir Treatment Restores the Anti‐HBV Immune response?
por: Beudeker, Boris J.B., et al.
Publicado: (2021)

Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
por: Qi, Ruoyao, et al.
Publicado: (2023)

The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis
por: Peng, Dan, et al.
Publicado: (2020)

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA
por: Shi, Hong, et al.
Publicado: (2016)

Entecavir resistance in a patient with treatment-naïve HBV: A case report
por: Marino, Andrea, et al.
Publicado: (2021)

A systems pharmacology-oriented discovery of a new therapeutic use of the TCM formula Liuweiwuling for liver failure
por: Wang, Jia-bo, et al.
Publicado: (2018)

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study
por: Ye, Feng, et al.
Publicado: (2022)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
por: Huang, Yan, et al.
Publicado: (2022)

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
por: Chen, Jian-Lin, et al.
Publicado: (2016)

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients
por: Liu, Xin, et al.
Publicado: (2023)

Effect of Liuweiwuling tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis: A protocol for a systematic review and meta-analysis
por: Li, Ding, et al.
Publicado: (2020)

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
por: Zhang, Xi, et al.
Publicado: (2021)

S gene mutations of HBV in children with HBV-associated glomerulonephritis
por: Lu, Hongzhu, et al.
Publicado: (2012)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B
por: Pawłowska, M., et al.
Publicado: (2011)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Immunostimulatory siRNA with a uridine bulge leads to potent inhibition of HBV and activation of innate immunity
por: Lan, Tingyu, et al.
Publicado: (2021)

Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy
por: Ma, Yaxian, et al.
Publicado: (2021)

Serum Sphingolipids Reflect the Severity of Chronic HBV Infection and Predict the Mortality of HBV-Acute-on-Chronic Liver Failure
por: Qu, Feng, et al.
Publicado: (2014)

HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)
por: Wang, Wenhui, et al.
Publicado: (2022)

Different types of viral-host junction found in HBV integration breakpoints in HBV-infected patients
por: Ruan, Peng, et al.
Publicado: (2019)

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China
por: Li, Si-Yue, et al.
Publicado: (2011)

Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment
por: Zhang, Ji-Yuan, et al.
Publicado: (2010)

HBV integrated genomic characterization revealed hepatocyte genomic alterations in HBV-related hepatocellular carcinomas
por: Yang, Ming, et al.
Publicado: (2020)

The Investigation of HBV Pre-S/S Gene Mutations in Occult HBV Infected Blood Donors with anti-HBs Positive
por: Guo, Yan, et al.
Publicado: (2022)

Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
por: Yang, Jianming, et al.
Publicado: (2023)

New Anti-HBV C-Boivinopyranosyl Flavones from Alternanthera philoxeroides
por: Li, Bin, et al.
Publicado: (2016)

Comparison and Correlation of Genetic Variability of the HBV Pre-S Region in HIV/HBV Co-Infected Patients: Quasispecies Perspective
por: Nie, Yuan, et al.
Publicado: (2020)

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
por: Liu, Jian, et al.
Publicado: (2023)

Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice
por: Ye, Lei, et al.
Publicado: (2017)

TLR3 Plays Significant Roles against HBV-Associated HCC
por: Chen, Xiao-lan, et al.
Publicado: (2015)

ACE2 and TMPRSS2 Expression in Hepatocytes of Chronic HBV Infection Patients
por: Hu, Xiao-Xiao, et al.
Publicado: (2021)

An Integrative Pharmacology Based Analysis of Refined Liuweiwuling Against Liver Injury: A Novel Component Combination and Hepaprotective Mechanism
por: Gao, Yuan, et al.
Publicado: (2021)

Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening
por: Wang, Hui, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bi446n2f7k9rcf77rejcuact3k